We [66] and others [67] have previously shown that the expression of above median levels of LAAs, such as SSX2IP alone, or in combination with SURVIVIN and receptor for hyaluronan-mediated motility (RHAMM), in presentation AML patients who lack cytogenetic rearrangements, can predict survival following conventional treatment (chemotherapy). This evidence concerns the gene BIRC5 and acute myeloid leukemia.